rs201579340
Variant names:
Variant summary
Our verdict is Benign. The variant received -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2
The NM_000512.5(GALNS):c.633+22T>C variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000842 in 1,609,932 control chromosomes in the GnomAD database, including 20 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.00068 ( 2 hom., cov: 33)
Exomes 𝑓: 0.00086 ( 18 hom. )
Consequence
GALNS
NM_000512.5 intron
NM_000512.5 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.293
Publications
0 publications found
Genes affected
GALNS (HGNC:4122): (galactosamine (N-acetyl)-6-sulfatase) This gene encodes N-acetylgalactosamine-6-sulfatase which is a lysosomal exohydrolase required for the degradation of the glycosaminoglycans, keratan sulfate, and chondroitin 6-sulfate. Sequence alterations including point, missense and nonsense mutations, as well as those that affect splicing, result in a deficiency of this enzyme. Deficiencies of this enzyme lead to Morquio A syndrome, a lysosomal storage disorder. [provided by RefSeq, Jul 2008]
GALNS Gene-Disease associations (from GenCC):
- mucopolysaccharidosis type 4AInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, ClinGen, Labcorp Genetics (formerly Invitae), Orphanet, Genomics England PanelApp
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -16 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.92).
BP6
Variant 16-88836179-A-G is Benign according to our data. Variant chr16-88836179-A-G is described in ClinVar as Likely_benign. ClinVar VariationId is 256334.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS2
High Homozygotes in GnomAd4 at 2 AR gene
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GALNS | NM_000512.5 | c.633+22T>C | intron_variant | Intron 6 of 13 | ENST00000268695.10 | NP_000503.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| GALNS | ENST00000268695.10 | c.633+22T>C | intron_variant | Intron 6 of 13 | 1 | NM_000512.5 | ENSP00000268695.5 |
Frequencies
GnomAD3 genomes AF: 0.000677 AC: 103AN: 152164Hom.: 2 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
103
AN:
152164
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.00143 AC: 358AN: 249804 AF XY: 0.00195 show subpopulations
GnomAD2 exomes
AF:
AC:
358
AN:
249804
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000860 AC: 1253AN: 1457650Hom.: 18 Cov.: 31 AF XY: 0.00113 AC XY: 817AN XY: 725394 show subpopulations
GnomAD4 exome
AF:
AC:
1253
AN:
1457650
Hom.:
Cov.:
31
AF XY:
AC XY:
817
AN XY:
725394
show subpopulations
African (AFR)
AF:
AC:
2
AN:
33362
American (AMR)
AF:
AC:
19
AN:
44650
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
26098
East Asian (EAS)
AF:
AC:
0
AN:
39682
South Asian (SAS)
AF:
AC:
757
AN:
86096
European-Finnish (FIN)
AF:
AC:
7
AN:
52866
Middle Eastern (MID)
AF:
AC:
20
AN:
5762
European-Non Finnish (NFE)
AF:
AC:
400
AN:
1108880
Other (OTH)
AF:
AC:
48
AN:
60254
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.474
Heterozygous variant carriers
0
78
156
234
312
390
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.000676 AC: 103AN: 152282Hom.: 2 Cov.: 33 AF XY: 0.000819 AC XY: 61AN XY: 74470 show subpopulations
GnomAD4 genome
AF:
AC:
103
AN:
152282
Hom.:
Cov.:
33
AF XY:
AC XY:
61
AN XY:
74470
show subpopulations
African (AFR)
AF:
AC:
2
AN:
41572
American (AMR)
AF:
AC:
27
AN:
15294
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3472
East Asian (EAS)
AF:
AC:
0
AN:
5182
South Asian (SAS)
AF:
AC:
36
AN:
4830
European-Finnish (FIN)
AF:
AC:
1
AN:
10616
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
35
AN:
67998
Other (OTH)
AF:
AC:
2
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.507
Heterozygous variant carriers
0
6
12
18
24
30
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
4
AN:
3478
ClinVar
Significance: Likely benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:2
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided
- -
May 31, 2017
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing
- -
not specified Benign:1
-
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.